<img src="https://publish-01.obsidian.md/access/744ac39d33cabbc297b91373bfcac24d/bin/images/Indonesia_map.png" alt="Indonesia" class="page-header-sidebar-image"> Indonesia has provisions in its legislation relating to the granting of compulsory licences. These can be found in the Patent Law No. 13 of 2016. Under the Indonesian Patent Law, compulsory licenses can be granted under the following circumstances: - Non-Working of the Patent: If a patented invention is not exploited within 36 months from the date of grant, any party may request a compulsory license. The law aims to prevent patents from remaining dormant and to encourage their utilization for commercial and public health purposes. - Public Interest Considerations: A compulsory license may be granted if the patent holder or licensee implements the patent in a manner that contravenes public interest, such as actions leading to monopolistic practices or unfair competition. - National Emergencies or Public Health Crises: The Indonesian government can grant compulsory licenses to address public health emergencies, including the importation of patented drugs not locally produced and the exportation of locally produced patented drugs to other countries facing health crises. More information can be found [here](https://www.wipo.int/wipolex/en/legislation/details/16392?). ## Compulsory licences Indonesia has granted compulsory licence for: - [[EFV]] - [[Remdesivir]] - [[NVP, 3TC]] - [[Favipiravir]] - [[ABC, DDI, EFV, EFV-FTC-TDF, LPV-r, TDF, FTC-TDF]] ## Generic manufacturers Indonesia has its own generic manufacturer: [Kalbe Farma](https://www.kalbe.co.id/en).